US Market News
1月前
Why Medtech Giants Are Quietly Paying Up for AI DiagnosticsApril 29, 2026 10:30 AM
PR Newswire (Canada)
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Medtronic (NYSE: MDT), Danaher (NYSE: DHR), Profound Medical (NASDAQ: PROF), and DexCom (NASDAQ: DXCM).
Hospitals are voting with their wallets too. A fresh C-suite survey shows 57% now rank AI clinical solutions as their top technology priority for 2026 to 2027, up from just 19% in 2023[3]. The FDA has made it clear that real-world clinical evidence is now central to clearing AI software, which is exactly why institutional buyers are paying a clinical validation premium for platforms that already have multi-site data behind them[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just picked up a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform, VMS+™ 4.0. The Edison Awards are widely considered one of the most prestigious innovation prizes in the world, often called "the Oscars of Innovation," and past Gold winners include Abbott, Medtronic, and Boston Scientific. For a small-cap medtech company out of Toronto, that is serious company to keep.The technology behind the award takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. VMS+™ 4.0 is already deployed in hospitals across the United States, Canada, the United Kingdom, and Europe, which is a key reason the Edison judges took notice. Their evaluation process places heavy weight on technologies that have moved past the pilot stage and into real clinical use.That momentum is showing up in VentriPoint's commercial pipeline. The company recently announced a collaboration with the Health Division of the Montecristo Group to roll out VMS+™ across Costa Rica's public and private hospital networks. The Montecristo Group's Hospital Metropolitano also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States. VentriPoint also recently partnered with First Light Health, an Indigenous-owned medical services company, to bring cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. That program builds on an earlier partnership with the Nisga'a Valley Health Authority in northern BC. South of the border, the company signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge," said Hugh MacNaught, CEO of VentriPoint.VentriPoint holds regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform is vendor-agnostic, meaning it works with ultrasound equipment from any manufacturer, and is built on more than a decade of proprietary Knowledge Based Reconstruction technology. The core value proposition is MRI-grade cardiac imaging at a fraction of the cost, deployable anywhere a standard ultrasound machine already sits. With a growing global footprint, a validated technology platform, and independent recognition from one of the world's top innovation bodies, VentriPoint is positioning itself as a name to watch in precision health.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointOther industry developments and happenings in the market include:Medtronic (NYSE: MDT) completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease diagnosis and treatment, for $585 million with potential additional earn-out payments. The deal follows a 2022 co-promotion agreement and brings the CathWorks FFRangio System, an AI-powered, drug-free, wire-free coronary assessment platform, into Medtronic's interventional cardiology portfolio."The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic. "Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide."The FFRangio System recently demonstrated non-inferiority to wire-based physiology in the ALL-RISE randomized control trial, which enrolled more than 1,900 patients across 59 sites globally. The acquisition is expected to be immaterial to Medtronic's fiscal year 2027 earnings and neutral to accretive thereafter, continuing the company's strategy of targeted tuck-in acquisitions to strengthen its core franchises.Danaher (NYSE: DHR) reported first quarter 2026 results showing revenues of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted diluted EPS growing 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by strength in Bioprocessing and better-than-expected Life Sciences performance."Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth," said Rainer M. Blair, President and CEO of Danaher. "On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Danaher raised its full year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, up from prior guidance of $8.35 to $8.50, and expects full year core revenue growth of 3% to 6%. The company also announced its intention to acquire Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, citing opportunities to enhance performance through the Danaher Business System and its global scale.Profound Medical (NASDAQ: PROF) is highlighting its TULSA-PRO system across seven presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15. The commercial-stage medical device company's AI-powered, MRI-guided TULSA Procedure treats prostate cancer and benign prostatic hyperplasia without incisions, eliminating procedural blood loss and overnight hospital stays while minimizing side effects such as urinary incontinence and erectile dysfunction."Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, CEO and Chairman of Profound Medical. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."Presentations will feature data from the Level 1 post-market CAPTAIN randomized controlled trial comparing TULSA against robotic prostatectomy for intermediate-risk prostate cancer. Profound Medical also commercializes Sonalleve, an MRI-guided therapy addressing bone metastases pain palliation, uterine fibroids, and adenomyosis, with its technologies approved across major global markets including the United States, Europe, and Canada.DexCom (NASDAQ: DXCM) is showcasing new clinical evidence at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, reinforcing the role of continuous glucose monitoring across all diabetes types. A multi-center primary care registry study showed that after one year of Dexcom G7 use, people with Type 2 diabetes not on insulin therapy saw significant improvements in A1C and weight management, while claims data linked Dexcom CGM initiation to meaningful reductions in DKA-related hospitalizations and emergency room visits in both children and adults with Type 1 diabetes."There is no better global stage than ATTD to showcase how we're shaping the future of glucose biosensing around the world," said Jake Leach, president and chief executive officer at DexCom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin."Beyond the clinical data, DexCom is presenting its near- and long-term product roadmap, including upcoming features for Dexcom G7, Dexcom G7 15 Day, and Stelo, its health and wellness offering. The company recently launched Dexcom G7 15 Day in the U.S. and continues expanding its Dexcom Academy HCP education platform across Europe and the Middle East.Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market https://www.sikich.com/insight/q1-2026-healthcare-ma-market-update/ https://hitconsultant.net/2026/03/24/sage-growth-partners-health-it-purchasing-forecast-2026-2027-ai-roi/ https://www.fda.gov/news-events/fda-voices/real-world-evidence-advancing-regulatory-decision-making-medical-devices Logo - https://mma.prnewswire.com/media/2838876/5919929/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/why-medtech-giants-are-quietly-paying-up-for-ai-diagnostics-302757277.html
Original: Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
US Market News
2月前
Danaher Reports First Quarter 2026 ResultsApril 21, 2026 6:00 AM
PR Newswire (US)
WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.Key First Quarter 2026 ResultsNet earnings were $1.0 billion, or $1.45 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 9.5% to $2.06.Revenues increased 3.5% year-over-year to $6.0 billion and non-GAAP core revenue increased 0.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Strong Q1 earnings performance enabling increased full year 2026 adjusted diluted net earnings per common share guidance.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth. On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Mr. Blair continued, "We were also pleased to announce our intention to acquire Masimo Corporation, a leading provider of mission-critical pulse oximetry and patient monitoring solutions in acute care settings. We believe there are clear opportunities to enhance Masimo's performance through DBS and our global scale. Looking ahead, the strength of our balance sheet and free cash flow generation provides additional capacity for value-creating capital deployment."Second Quarter and Full Year 2026 OutlookDanaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which for the second quarter and full year 2026 is estimated to increase sales by 0.5% in both periods, assuming the currency exchange rates in effect as of March 27, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP.For the second quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.For full year 2026, the Company continues to expect that non-GAAP core revenue will increase in the 3% to 6% range year-over-year. The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.35 to $8.55 versus previous guidance of $8.35 to $8.50.Conference Call and Webcast InformationDanaher will discuss its first quarter results and financial guidance for the second quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.The conference call can be accessed by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ126). A replay of the conference call will be available shortly after the conclusion of the call and until May 5, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALSIn addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).FORWARD-LOOKING STATEMENTS AND OTHER INFORMATIONStatements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the second quarter and full year 2026, the Company's anticipated acquisition of Masimo Corporation (which remains subject to customary closing conditions, including regulatory approval) and anticipated opportunities with respect thereto, anticipated free cash flow generation, the Company's prospects for capital deployment and driving long-term shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including any debt we incur to finance the pending acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our pending acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED CONDENSED STATEMENTS OF EARNINGS ($ and shares in millions, except per share amounts)(unaudited)
Three-Month Period Ended
March 27, 2026
March 28, 2025Sales$ 5,951
$ 5,741Cost of sales(2,360)
(2,230)Gross profit3,591
3,511Operating costs:
Selling, general and administrative expenses(1,860)
(1,858)Research and development expenses(387)
(379)Operating profit1,344
1,274Nonoperating income (expense):
Other income (expense), net(73)
(79)Interest expense(63)
(72)Interest income27
6Earnings before income taxes1,235
1,129Income taxes(206)
(175)Net earnings $ 1,029
$ 954Net earnings per common share:
Basic$ 1.45
$ 1.33Diluted$ 1.45
$ 1.32Average common stock and common equivalent shares outstanding:
Basic707.9
716.3Diluted711.2
720.8This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).
Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share
Three-Month Period Ended
March 27, 2026
March 28, 2025Diluted Net Earnings Per Common Share (GAAP)$ 1.45
$ 1.32Amortization of acquisition-related intangible assets A0.61
0.57Fair value net (gains) losses on investments B0.11
0.12Acquisition-related items C0.02
—Impairments D—
0.02Gain on a product line disposition E—
(0.01)Tax effect of the above adjustments F(0.13)
(0.13)Discrete tax adjustments G—
(0.01)Adjusted Diluted Net Earnings Per Common Share (Non-GAAP)$ 2.06
$ 1.88Notes to Reconciliation of GAAP to Non-GAAP Financial MeasuresA Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):
Three-Month Period Ended
March 27, 2026
March 28, 2025Pretax$ 434
$ 410After-tax360
340B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended
March 27, 2026
March 28, 2025Pretax$ 77
$ 90After-tax59
68C Transaction costs related to the anticipated acquisition of Masimo Corporation ("Masimo") in the three-month period ended March 27, 2026 ($17 million pretax as reported in this line item, $15 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.D Impairment charges related to a facility in the Biotechnology segment recorded in the three-month period ended March 28, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).E Gain on a product line disposition in the three-month period ended March 28, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).F This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.G There were no net discrete tax adjustments and other tax-related adjustments for the three-month period ended March 27, 2026, as the release of reserves for uncertain tax positions due to the expiration of statutes of limitations was offset by charges related to changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the three-month period ended March 28, 2025, include the impact of net discrete tax benefits of $10 million related primarily to changes in estimates of prior year tax filing positions, release of reserves for uncertain tax positions due to the expiration of statutes of limitations and excess tax benefits from stock-based compensation, net of charges related to changes in estimates associated with prior period uncertain tax positions.
Sales Growth (Decline) by Segment and Core Sales Growth (Decline) by Segment
% Change Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Period
Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsTotal sales growth (decline) (GAAP)3.5 %
11.5 %
3.5 %
(1.5) %Impact of:
Currency exchange rates (3.0) %
(4.5) %
(3.0) %
(2.5) %Core sales growth (decline) (non-GAAP)0.5 %
7.0 %
0.5 %
(4.0) %Forward-Looking Information
% Change Three-
Month Period
Ending June 26,
2026 vs.
Comparable 2025
Period
% Change Year
Ending December
31, 2026 vs.
Comparable 2025
PeriodCore sales growth (non-GAAP)
Biotechnology+Mid-single digit
~+6.0%Life Sciences+Up slightly
+Up slightlyDiagnosticsFlat
+Low-single digitTotal Company+Low-single digit
+3.0% - +6.0%
Three-Month
Period Ending June 26, 2026
Year Ending December 31, 2026Adjusted operating profit margin (non-GAAP)~26.5 %
Adjusted diluted net earnings per common share (non-GAAP)
$8.35 - $8.55Cepheid respiratory revenue ($ in billions)
~$1.6 - $1.7Impact of currency exchange rates on sales H~+0.5 %
~+0.5 %Corporate expense I ($ in millions)~$(90)
~$(360)Interest expense, net J ($ in millions)~$(40)
~$(140)Effective tax rate ~17.0 %
~17.0 %Average adjusted diluted shares (in millions)~712.0
~714.0H Impact of currency exchange rates on sales for the second quarter and full year 2026 assumes the currency exchange rates in effect as of March 27, 2026.I Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.J Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of March 27, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding, nor does it include an estimate for incremental net interest expense related to the financing for the anticipated acquisition of Masimo Corporation ("Masimo").Cash Flow and Free Cash Flow($ in millions)
Three-Month Period Ended
March 27, 2026
March 28, 2025Total Cash Flow:
Net cash provided by operating activities (GAAP)$ 1,322
$ 1,299Total cash used in investing activities (GAAP)$ (249)
$ (242)Total cash provided by (used in) financing activities (GAAP)$ 46
$ (1,255)
Free Cash Flow:
Net cash provided by operating activities (GAAP)$ 1,322
$ 1,299Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP)(237)
(245)Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)—
6Free cash flow (non-GAAP)$ 1,085
$ 1,060We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals"). Statement Regarding Non-GAAP MeasuresEach of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; andwith respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:With respect to the profitability-related non-GAAP measures:Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.Other Adjustments: With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.
View original content:https://www.prnewswire.com/news-releases/danaher-reports-first-quarter-2026-results-302747922.htmlSOURCE Danaher Corporation
Original: Danaher Reports First Quarter 2026 Results
US Market News
2月前
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesApril 9, 2026 9:00 AM
InvestorsHub NewsWireAI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesAINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice ("GMP") requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this evolving technological landscape.Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.Regulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing.Current obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.A more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Click here to view the custom infographic of the Oncotelic Therapeutics editorial.Embedded Intelligence Enables Continuous ComplianceHistorically, pharmaceutical manufacturing relied heavily on batch-based testing and manual recordkeeping to verify compliance. While these methods were sufficient in earlier production models, they often introduce delays and create opportunities for human error. Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.This shift supports initiatives from the U.S. Food and Drug Administration ("FDA"), which has encouraged the adoption of advanced manufacturing technologies and continuous production models. Programs such as the FDA's Emerging Technology Program and Advanced Manufacturing Technologies initiative promote the use of innovative systems designed to enhance reliability, improve product quality and minimize the risk of manufacturing failures or supply disruptions. These efforts highlight a transition from reactive oversight to proactive compliance strategies.AI technologies facilitate this transformation by regularly evaluating streams of production data, including variables such as temperature, pressure and material uniformity, to identify anomalies as they occur. Rather than detecting issues during post-production reviews, these systems enable immediate intervention, helping maintain product integrity. This ability supports real-time release testing, a model in which products are evaluated and approved based on live process data instead of delayed laboratory testing.As this approach gains adoption, companies such as Oncotelic Therapeutics are part of a broader ecosystem that increasingly views embedded intelligence as a core component of compliance. Their alignment with AI-enabled platforms reflects a growing understanding that compliance is no longer a discrete checkpoint, but an integrated function operating continuously across the manufacturing lifecycle.Heightened Regulation Accelerates Automation AdoptionRegulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records. Likewise, FDA expectations reinforce following ALCOA+ principles, which ensure that data is attributable, legible, contemporaneous, original and accurate.These rising standards are hastening the move toward automation. Manual processes, which have long been standard across pharmaceutical manufacturing, are now seen as potential sources of variability and documentation risk. According to the International Society for Pharmaceutical Engineering, digital transformation initiatives are becoming essential to improving compliance outcomes and reducing operational risk in modern pharmaceutical systems.AI-enhanced automation provides a solution by standardizing workflows and ensuring consistent data capture. These systems automatically generate audit-ready documentation, reducing reliance on human input while improving transparency and accuracy. In sterile manufacturing environments, where contamination risks must be minimized, automation also reduces human involvement, thereby reinforcing compliance outcomes.Within this regulatory environment, Oncotelic Therapeutics represents a wider strategic alignment with innovation driven by compliance requirements. As pharmaceutical companies increasingly prioritize automation and data integrity, organizations leveraging AI-enabled platforms are better positioned to meet evolving regulatory expectations.Pharma 4.0 Drives Intelligent Production EcosystemsThe idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing. Sparked by Industry 4.0, this model integrates digital technologies such as artificial intelligence, robotics and advanced analytics into interconnected production systems. Research indicates that these technologies are transforming biopharma operations by increasing productivity, improving product quality and supporting more agile, data-driven decision-making across the value chain.In such environments, manufacturing systems are fully connected, enabling data to move between equipment, quality systems and supply chain processes. AI-driven analytics use this data to optimize performance, anticipate maintenance needs and ensure compliance. This integration enhances traceability, enabling manufacturers to monitor every stage of production with greater precision.Large pharmaceutical companies are now employing these capabilities. Pfizer Inc. has implemented digital manufacturing programs that leverage AI and data-driven systems to improve efficiency and operational performance. Johnson & Johnson has invested in AI-powered platforms to enhance decision-making and streamline development processes, while Novartis AG is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments. These initiatives demonstrate a broader industry commitment to adopting intelligent manufacturing as a pathway to improved compliance and operational efficiency.Within this context, Oncotelic Therapeutics represents a growing class of entities operating at the intersection of biotechnology and digital innovation. As Pharma 4.0 adoption increases, organizations supporting AI-enabled systems are increasingly positioned to participate in scalable, data-driven manufacturing ecosystems.Efficiency Gains Reduce Cost, RiskThe process of bringing a new pharmaceutical product to market remains both time-consuming and expensive, often requiring more than a decade of development and substantial financial investment. A substantial part of these expenses are caused by high failure rates, increasing process complexity and inefficiencies across development and manufacturing stages. These obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.Deloitte has noted that digital transformation in life sciences manufacturing can boost operational efficiency by streamlining processes, increasing productivity and reducing errors. AI systems can evaluate both real-time and historical data to anticipate possible problems, allowing manufacturers to intervene before issues escalate.Continuous manufacturing, frequently supported by AI and advanced process control technologies, further improves efficiency by reducing reliance on large-batch production. Instead, it enables continuous processing with real-time monitoring, lowering inventory requirements and accelerating time-to-market. The FDA has actively supported this approach, recognizing its ability to improve product quality, reduce costs and provide a more flexible alternative to traditional batch manufacturing.The combination of reduced risk and improved efficiency creates a compelling value proposition for companies operating at the intersection of AI and biotechnology. In this environment, organizations such as Oncotelic Therapeutics reflect the growing importance of platforms capable of supporting intelligent automation and compliance as the industry seeks to manage costs more effectively.AI, Robotics Reshape Biotech InfrastructureA more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Modern manufacturing facilities increasingly rely on robotic systems to automate complex processes such as aseptic filling, material handling and inspection, decreasing the need for human intervention while improving precision and efficiency. In addition, AI-driven systems monitor operations in real time, analyzing data to detect irregularities and optimize performance, supporting continuous compliance.This meeting of technology is especially significant in sterile manufacturing environments, where minimizing human involvement is essential to reducing contamination risk. Robotics provide precision and consistency, while AI systems continuously monitor environmental conditions and process variables. These technologies come together to make integrated systems that sustain both compliance and operational quality.Market data highlights the reach of this transformation. The global pharmaceutical manufacturing sector, already valued in the hundreds of billions of dollars, is expected to reach $1 trillion in the coming years. Investment is increasingly directed toward automation, digital infrastructure and AI-enabled production systems designed to improve efficiency and regulatory compliance. This trend indicates a broader reallocation of capital toward technologies that enhance scalability, precision and operational control.As this movement continues to climb upward, companies aligned with AI-driven platforms may benefit from sustained growth and improved margins. Positioned within this evolving landscape, Oncotelic Therapeutics represents the type of organization that could participate in this transformation, where intelligent automation and integrated compliance redefine pharmaceutical manufacturing.AI and Robotics Drive Next Phase of TransformationArtificial intelligence and robotics are rapidly reshaping industrial operations, enabling companies to improve efficiency, reduce manual intervention and unlock new levels of productivity. Across manufacturing, infrastructure and life sciences, organizations are increasingly deploying intelligent automation systems that combine real-time data, machine learning and advanced robotics to streamline workflows and support decision-making.Rockwell Automation Inc. (NYSE: ROK) announced a major step in real-time intelligence for industrial teams. The company introduced its integration of NVIDIA Nemotron Nano, a purpose-built small language model ("SLM") optimized for FactoryTalk(R) Design Studio(TM) and other Rockwell product workflows. In collaboration with NVIDIA, Rockwell is leveraging the open-source Nemotron-Nano-9B-v2 model and NVIDIA NeMo to deliver an edge-based generative AI capability designed specifically for industrial environments.Emerson Electric Co. (NYSE: EMR) has introduced a new AI-powered environment to enhance upstream lifecycle decision making. Emerson's AspenTech Subsurface Intelligence(TM) ("ASI") is an open, cloud-native agentic environment that incorporates AI to transform the user experience and accelerate subsurface-related decision making while leveraging existing investments in legacy applications. ASI fulfills a critical industry need to work in an agile, multidisciplinary manner, optimize production and improve access to information trapped throughout various parts of the organization.Thermo Fisher Scientific Inc. (NYSE: TMO) integrates AI and robotics into laboratory and semiconductor environments with its Thermo Scientific Vulcan(TM) Automated Lab. The platform is designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system enhances productivity, increases yield and reduces operating costs for semiconductor manufacturers.Danaher Corp. (NYSE: DHR) announced a collaboration designed to enhance life science lab connectivity by integrating automated imaging and detection systems into research workflows. Molecular Devices, LLC., a leading provider of high-performance life science solutions and an operating company of Danaher is partnering with Automata, a London-based lab automation company developing fully integrated, AI-ready platforms for life science researchers. As labs face mounting pressure to boost throughput and data quality while managing limited hands-on resources, new integrations between Molecular Devices' imaging and detection systems and Automata's LINQ platform will provide a scalable, interoperable foundation for fully connected research workflows.These developments reflect a broader transformation across industrial and scientific sectors, where AI and robotics are becoming foundational technologies rather than experimental tools. As companies continue to integrate intelligent systems into core operations, these advancements highlight the growing importance of automation in driving efficiency, scalability and long-term competitiveness across the global economy.For more information, visit Oncotelic Therapeutics Inc.
Original: AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
US Market News
4月前
Danaher To Acquire Masimo CorporationFebruary 17, 2026 8:00 AM
PR Newswire (US)
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2027 estimated EBITDA including the full benefit of expected annual synergies1.Rainer M. Blair, President and Chief Executive Officer, Danaher, said: "We are excited to welcome the Masimo team to Danaher. We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher. Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise. With the Danaher Business System and our global scale, we see opportunities to expand Masimo's reach and continue improving outcomes for patients, particularly those in acute care settings."Julie Sawyer Montgomery, Executive Vice President for Diagnostics, Danaher, said: "Masimo's advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision making in critical settings."Upon completion of the transaction, Masimo will be a standalone operating company within Danaher's Diagnostics segment along with Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics. Masimo is expected to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion of the acquisition. Masimo is expected to deliver high-single digit core revenue growth over the long-term, accelerating Danaher's Diagnostics segment core revenue growth profile.Under Danaher's ownership, Masimo is expected to generate EBITDA of more than $530 million in 2027. Additionally, Danaher expects to realize more than $125 million of annual cost synergies and more than $50 million of annual revenue synergies by the fifth full year following completion of the acquisition.The transaction is anticipated to close in the second half of 2026 and is subject to customary conditions, including receipt of applicable regulatory clearances and Masimo shareholder approval. Danaher expects to fund the acquisition using cash on hand and proceeds from debt financing.Citi acted as financial advisor to Danaher. Kirkland & Ellis LLP served as legal advisor to Danaher in connection with the Transaction.Core revenue growth, adjusted diluted net earnings per common share and EBITDA are non-GAAP measures; please see "Non-GAAP Measures" below for additional information. 1 2027 estimated EBITDA including the full benefit of expected annual synergies refers to 2027 estimated EBITDA adjusted to include the full benefit of annual synergies expected to be achieved by the fifth full year following acquisition.A note containing additional financial and other information relating to Danaher's anticipated acquisition of Masimo has been posted to the "Investors" section of Danaher's public website (www.danaher.com ).ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.NON-GAAP MEASURES
This communication contains the non-GAAP financial measures of core revenue growth, adjusted diluted net earnings per common share and EBITDA. Core revenue growth excludes the impact of currency translation and the effect of acquisitions and divested product lines. Adjusted diluted net earnings per common share in this calculation excludes amortization of intangible assets, purchase accounting charges and transaction expenses attributable to the acquisition. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. The items excluded from these non-GAAP measures have been excluded because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to the business' commercial performance during the particular period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.Each of these non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing the results of Danaher and/or the acquired business, as applicable, that, when reconciled to the corresponding GAAP measure, help our investors understand the impact of the acquisition to Danaher's profitability, growth and future prospects. Management uses these non-GAAP measures to measure Danaher's operating and financial performance and to assess anticipated operating and financial performance of the acquired business.Danaher does not reconcile these forecasted non-GAAP measures to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP. IMPORTANT INFORMATION AND WHERE TO FIND IT
In connection with the proposed transaction (the "Transaction"), Masimo and Danaher intend to file relevant materials with the SEC, including Masimo's proxy statement in preliminary and definitive form. Masimo will mail the definitive proxy statement and a proxy card to its stockholders in advance of the stockholders meeting in connection with the Transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Masimo with the SEC. INVESTORS AND STOCKHOLDERS OF MASIMO ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED BY EACH OF DANAHER AND MASIMO WITH THE SEC IN CONNECTION WITH THE TRANSACTION OR INCORPORATED BY REFERENCE THEREIN, INCLUDING MASIMO'S PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT MASIMO, DANAHER, AND THE TRANSACTION AND RELATED MATTERS. Investors and stockholders are or will be able to obtain these documents (when they are available) free of charge from the SEC's website at www.sec.gov. Danaher and Masimo make available free of charge at the Danaher website at https://investors.danaher.com/sec-filings and Masimo's website at https://investor.masimo.com/overview/, respectively, copies of documents they file with, or furnish to, the SEC. The contents of the websites referenced above will not be deemed to be incorporated by reference into the proxy statement.PARTICIPANTS IN THE SOLICITATION
This communication does not constitute a solicitation of a proxy. Masimo, Danaher and their respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be "participants" in the solicitation of proxies from stockholders of Masimo in favor of the Transaction. Information about Masimo's directors and executive officers is set forth in Masimo's Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Stockholders, which was filed with the SEC on March 26, 2025, including under the headings entitled "Our Board of Directors", "Our Executive Officers", "Executive Compensation", "Ownership of our Stock", "Proposal 1: To Elect Three Class II and Two Class III Directors as Named in our Proxy Statement", "Proposal 3: To Provide an Advisory Vote to Approve the Compensation of our Named Executive Officers", and "Transactions with Related Persons, Promoters and Certain Control Persons", and which is available at:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000937556/000110465925027887/tm259245-2_def14a.htm, and Masimo's Current Report on Form 8-K filed with the SEC on June 12, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000937556/000093755625000091/masi-20250606.htm, and Masimo's Current Report on Form 8-K filed with the SEC on August 19, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0000937556/000093755625000127/masi-20250818.htm. Information about Danaher's directors and executive officers is set forth in Danaher's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 20, 2025 under the heading entitled "Information About Our Executive Officers", and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000043/dhr-20241231.htm, and Danaher's Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Stockholders, which was filed with the SEC on March 26, 2025, including under the headings entitled "Board of Directors and Committees of the Board," "2024 Annual Executive Compensation," "Beneficial Ownership of Danaher Common Stock by Directors, Officers and Principal Shareholders," "Proposal 1 - Election of Directors," "Proposal 3 - Advisory Vote on Named Executive Officer Compensation," and "Certain Relationships and Related Transactions," and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000081/dhr-20250326.htm, and Danaher's Current Report on Form 8-K filed with the SEC on July 24, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000155/dhr-20250721.htm, and Danaher's Current Report on Form 8-K filed with the SEC on July 31, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000172/dhr-20250728.htm, and Danaher's Current Report on Form 8-K filed with the SEC on November 6, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000198/dhr-20251106.htm, and Danaher's Current Report on Form 8-K filed with the SEC on February 5, 2026, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361626000058/dhr-20260205.htm. To the extent holdings of Masimo's securities by its directors or executive officers have changed since the amounts set forth in such 2025 proxy statement, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, which are available at https://www.sec.gov/edgar/browse/?CIK=937556&owner=exclude. Additional information concerning the interests of Masimo's participants in the solicitation, which may, in some cases, be different than those of Masimo's stockholders generally, will be set forth in Masimo's proxy statement relating to the Transaction when it becomes available.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts included in this communication that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements, including, in particular, statements about the expected timing, completion and effects or benefits of the Transaction. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: (i) uncertainties as to the timing of the Transaction; (ii) the risk that the Transaction may not be completed on the anticipated terms in a timely manner or at all; (iii) the failure to satisfy any of the conditions to the consummation of the Transaction, including receiving, on a timely basis or otherwise, the required approval of the Transaction by Masimo's stockholders; (iv) the possibility that competing offers or acquisition proposals for Masimo will be made; (v) the possibility that any or all of the various conditions to the consummation of the Transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances which would require Masimo to pay a termination fee; (vii) the effect of the announcement or pendency of the transactions contemplated by the merger agreement on Masimo's or Danaher's ability to retain and hire key personnel, their ability to maintain relationships with their customers, suppliers and others with whom they do business, or their operating results and businesses generally; (viii) risks related to diverting management's attention from Masimo's or Danaher's ongoing business operations; (ix) the risk that stockholder litigation in connection with the transactions contemplated by the merger agreement may result in significant costs of defense, indemnification and liability; (x) certain restrictions during the pendency of the Transaction that may impact Masimo's or Danaher's ability to pursue certain business opportunities or strategic transactions; (xi) the risk that any announcements relating to the Transaction could have adverse effects on the market price of Masimo's or Danaher's common stock, including if the proposed transaction is not consummated; (xii) risks that the benefits of the Transaction are not realized when and as expected; (xiii) legislative, regulatory and economic developments; and (xiv) other factors discussed in the "Risk Factors" sections of Masimo's and Danaher's most recent periodic and current reports filed with the SEC, all of which you may obtain for free on the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.NO OFFER OR SOLICITATION
This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
View original content:https://www.prnewswire.com/news-releases/danaher-to-acquire-masimo-corporation-302689266.htmlSOURCE Danaher Corporation
Original: Danaher To Acquire Masimo Corporation
US Market News
4月前
Danaher Reports Fourth Quarter and Full Year 2025 ResultsJanuary 28, 2026 11:00 AM
PR Newswire (US)
WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.Key Fourth Quarter 2025 ResultsNet earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 ResultsNet earnings were $3.6 billion, or $5.03 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.5% to $7.80.Revenues increased 3.0% year-over-year to $24.6 billion and non-GAAP core revenue increased 2.0% year-over-year.Operating cash flow was $6.4 billion and non-GAAP free cash flow was $5.3 billion.2025 Innovation HighlightsLaunched innovative new products and solutions, which strengthened Danaher's position as a trusted leader in life sciences and diagnostics.Cytiva expanded its Xcellerex X-platform bioreactor with 500L and 2,000L formats, helping customers improve yields while reducing the time and cost of biologic manufacturing.SCIEX introduced the ZenoTOF 8600 high-resolution mass spectrometer, helping researchers accelerate drug development timelines.Beckman Coulter Diagnostics expanded the assay menu of the DxI 9000 immunoassay platform, with notable progress in neurodegenerative disease assays.Cepheid received FDA clearance for its Xpert GI Panel, a rapid multiplex PCR test that detects 11 common gastrointestinal pathogens from a single patient sample.Rainer M. Blair, President and Chief Executive Officer, stated, "We delivered a strong finish to the year with better-than-expected performance across our portfolio. We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences. Our teams' disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations."Mr. Blair continued, "Looking ahead, we expect the gradual improvement in our end markets we saw through 2025 to continue, and we believe the combination of our differentiated portfolio, the power of the Danaher Business System, and the strength of our balance sheet positions Danaher for long-term value creation as we move into 2026 and beyond."First Quarter and Full Year 2026 OutlookThe Company does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which for the first quarter and full year 2026 is estimated to increase sales by 3.5% and 1.0%, respectively, assuming the currency exchange rates in effect as of December 31, 2025) because the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP. For the first quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.For full year 2026, the Company expects that non-GAAP core revenue will increase in the 3% to 6% range year-over-year. The Company is also initiating full year adjusted diluted net earnings per common share guidance in the range of $8.35 to $8.50.Conference Call and Webcast InformationDanaher will discuss its fourth quarter results and financial guidance for the first quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.The conference call can be accessed by dialing 800-245-3047 within the U.S. or by dialing +1 203-518-9765 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ425). A replay of the conference call will be available shortly after the conclusion of the call and until February 11, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALSIn addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).FORWARD-LOOKING STATEMENTS AND OTHER INFORMATIONStatements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the first quarter and full year 2026, the impact of recently-launched products, the anticipated improvement in end-markets, Danaher's long-term competitive positioning, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the healthcare industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty, government shutdowns and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2024 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2025. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share
Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024Diluted Net Earnings Per Common Share
From Continuing Operations (GAAP)$ 1.66
$ 1.49
$ 5.03
$ 5.29Amortization of acquisition-related intangible assetsA0.60
0.56
2.37
2.21Fair value net (gains) losses on investmentsB0.14
0.09
0.35
0.08ImpairmentsC0.02
0.06
0.78
0.36Gain on sale of a facilityD(0.02)
—
(0.02)
—Resolution of an acquisition contingencyE(0.01)
—
(0.01)
—Contract termination expenseF—
0.08
—
0.08Gain on a product line dispositionG—
—
(0.01)
—Acquisition-related itemsH—
—
—
0.03Tax effect of the above adjustmentsI(0.13)
(0.13)
(0.67)
(0.51)Discrete tax adjustmentsJ(0.04)
(0.01)
(0.02)
(0.07)Rounding0.01
—
—
0.01Adjusted Diluted Net Earnings Per
Common Share From Continuing
Operations (Non-GAAP)$ 2.23
$ 2.14
$ 7.80
$ 7.48 Notes to Above ReconciliationAAmortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):
Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024Pretax$ 428
$ 408
$ 1,697
$ 1,631After-tax359
338
1,412
1,346
BNet (gains) losses, including impairments, on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024Pretax$ 99
$ 64
$ 248
$ 57After-tax75
48
188
39
CImpairment charges related to a facility in the Life Sciences segment recorded in the three-month period and year ended December 31, 2025 ($14 million pretax as reported in this line item, $11 million after-tax), technology, other intangible assets and a facility in the Biotechnology segment recorded in the year ended December 31, 2025 ($101 million pretax as reported in this line item, $69 million after-tax), a trade name in the Diagnostics segment recorded in the year ended December 31, 2025 ($15 million pretax as reported in this line item, $12 million after-tax), a trade name in the Life Sciences segment recorded in the year ended December 31, 2025 ($432 million pretax as reported in this line item, $328 million after-tax), a trade name in the Diagnostics segment recorded in the three-month period and year ended December 31, 2024 ($43 million pretax as reported in this line item, $32 million after-tax) and a trade name in the Life Sciences segment recorded in the year ended December 31, 2024 ($222 million pretax as reported in this line item, $169 million after-tax).
DGain on the sale of a facility in the three-month period and year ended December 31, 2025 ($11 million pretax as reported in this line item, $8 million after-tax).
EResolution of an acquisition contingency in the three-month period and year ended December 31, 2025 ($10 million pretax as reported in this line item, $8 million after-tax).
FLoss on the termination of a commercial agreement in the Diagnostics segment in the three-month period and year ended December 31, 2024 ($56 million pretax as reported in this line item, $56 million after-tax).
GGain on a product line disposition in the year ended December 31, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).
HCosts incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc ("Abcam") for the year ended December 31, 2024 ($25 million pretax as reported in this line item, $19 million after-tax).
IThis line item reflects the aggregate tax effect of all non-tax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.
JDiscrete tax adjustments and other tax-related adjustments for the three-month period ended December 31, 2025, include the impact of net discrete tax benefits of $26 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to audit settlements and the expiration of statutes of limitation, partially offset by changes in estimates related to prior year tax filing positions and a valuation allowance recorded on certain tax credits in a foreign jurisdiction. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2025 include the impact of net discrete tax benefits of $14 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to audit settlements and the expiration of statutes of limitation and the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change, partially offset by charges related to changes in estimates associated with prior period uncertain tax positions and valuation allowances recorded on foreign operating losses and tax credits in certain foreign jurisdictions. Discrete tax adjustments for the three-month period ended December 31, 2024, include the impact of net discrete tax benefits of $4 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates related to prior year tax filing positions, net of charges related to changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2024 include the impact of net discrete tax benefits of $49 million due principally to net discrete tax benefits resulting from excess tax benefits from stock compensation, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates related to prior year tax filing positions, net of charges related to changes in estimates associated with prior period uncertain tax positions. DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(continued)
Sales Growth by Segment, Core Sales Growth (Decline) by Segment
% Change Three-Month Period Ended December 31, 2025 vs. Comparable
2024 Period
Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsTotal sales growth (GAAP)4.5 %
9.0 %
2.5 %
3.0 %Impact of:
Acquisitions/divestitures0.5 %
— %
— %
1.0 %Currency exchange rates (2.5) %
(3.0) %
(2.0) %
(2.0) %Core sales growth (non-GAAP)2.5 %
6.0 %
0.5 %
2.0 %
% Change Year Ended December 31, 2025 vs. Comparable 2024 Period
Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsTotal sales growth (GAAP)3.0 %
8.0 %
— %
1.5 %Impact of:
Acquisitions/divestitures— %
— %
(0.5) %
0.5 %Currency exchange rates (1.0) %
(1.5) %
(1.0) %
(0.5) %Core sales growth (decline) (non-GAAP)2.0 %
6.5 %
(1.5) %
1.5 % Other Supplemental Information($ in millions)
Three-Month Period Ended
December 31, 2025Cepheid respiratory revenue
~$500 Forecasted Core Sales Growth (Decline) by Segment and Adjusted Diluted Net Earnings Per Common Share.
% Change Three-Month Period
Ending March 27, 2026 vs.
Comparable 2025 Period
% Change Year Ending December
31, 2026 vs. Comparable 2025
PeriodBiotechnology+High-single digit
~+6.0%Life SciencesFlat/ -Low-single digit
FlatDiagnostics-Low-single digit
+Low-single digitTotal Company core sales growth (non-GAAP)+Low-single digit
+3.0% - +6.0%
Year Ending December 31, 2026Adjusted diluted net earnings per common share (non-GAAP)
$8.35 - $8.50 Supplemental Forward-Looking Information($ in millions)
Three-Month Period Ending March
27, 2026
Year Ending December 31, 2026Adjusted operating profit margin (non-GAAP) ~28.5%
Impact of currency exchange rates on sales1~+3.5%
~+1.0%Corporate expense2~$(90)
~$(360)Interest expense, net3~$(45)
~($180)Effective tax rate~17.0%
~17.0%Average adjusted diluted shares~714.0
~717.0
1Impact of currency exchange rates on sales for the first quarter and full year 2026 assumes the currency exchange rates in effect as of December 31, 2025.2Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.3Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of December 31, 2025 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding. DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(continued)
Operating Profit Margins and Year-Over-Year Core Operating Margin Changes
Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsThree-Month Period Ended December 31, 2024 Operating
Profit Margins from Continuing Operations (GAAP)21.80 %
27.20 %
18.50 %
23.70 %
Fourth quarter 2025 impact from operating profit margins
of businesses that have been owned for less than one
year or were disposed of during such period and did not
qualify as discontinued operations(0.10)
—
(0.05)
(0.20)
Fourth quarter 2025 resolution of an acquisition
contingency in the Diagnostics segment0.15
—
—
0.35
Fourth quarter 2024 impairment charge related to a trade
name in the Diagnostics segment, net of a 2025
impairment charge related to a facility in the Life
Sciences segment0.45
—
(0.70)
1.60
Fourth quarter 2024 loss on the termination of a
commercial arrangement in the Diagnostics segment0.85
—
—
2.15Year-over-year core operating profit margin changes for
the fourth quarter 2025 (defined as all year-over-year
operating profit margin changes other than the changes
identified in the line items above) (non-GAAP)(1.15)
(0.60)
(1.65)
(1.40)Three-Month Period Ended December 31, 2025 Operating
Profit Margins from Continuing Operations (GAAP)22.00 %
26.60 %
16.10 %
26.20 %
Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsYear Ended December 31, 2024 Operating Profit Margins
from Continuing Operations (GAAP)20.40 %
24.90 %
12.00 %
26.80 %
Full year 2025 impact from operating profit margins of
businesses that have been owned for less than one year
or were disposed of during such period and did not
qualify as discontinued operations(0.20)
—
(0.30)
(0.15)
Full year 2025 resolution of an acquisition contingency in
the Diagnostics segment0.05
—
—
0.10
Full year 2025 impairment charges related to trade
names in the Life Sciences and Diagnostics segments
and technology, other intangible assets and a facility in
the Biotechnology segment and a facility in the Life
Sciences segment, net of full year 2024 impairment
charges related to a trade name in each of the Life
Sciences and Diagnostics segments(1.20)
(1.30)
(3.05)
0.30
Full year 2024 loss on the termination of a commercial
arrangement in the Diagnostics segment0.25
—
—
0.60
Full year 2024 acquisition-related fair value adjustment to
inventory related to the acquisition of Abcam0.10
—
0.35
—Year-over-year core operating profit margin changes for
full year 2025 (defined as all year-over-year operating
profit margin changes other than the changes identified
in the line items above) (non-GAAP)(0.30)
2.00
(1.90)
(0.95)Year Ended December 31, 2025 Operating Profit Margins
from Continuing Operations (GAAP)19.10 %
25.60 %
7.10 %
26.70 % DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(continued)
Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations and Related Measures($ in millions)
Three-Month Period Ended
Year Ended
December 31,
2025
December 31,
2024
December 31,
2025
December 31,
2024Total Cash Flows from Continuing Operations:
Total cash provided by operating activities from continuing
operations (GAAP)$ 2,117
$ 2,019
$ 6,416
$ 6,688Total cash used in investing activities from continuing
operations (GAAP)$ (384)
$ (694)
$ (1,196)
$ (1,981)Total cash provided by (used in) financing activities from
continuing operations (GAAP)$ 1,322
$ (1,692)
$ (2,961)
$ (8,385)
Free Cash Flow from Continuing Operations:
Total cash provided by operating activities from continuing
operations (GAAP)$ 2,117
$ 2,019
$ 6,416
$ 6,688Less: payments for additions to property, plant & equipment
(capital expenditures) from continuing operations (GAAP)(371)
(516)
(1,156)
(1,392)Plus: proceeds from sales of property, plant & equipment
(capital disposals) from continuing operations (GAAP)23
1
33
13Free cash flow from continuing operations (non-GAAP)$ 1,769
$ 1,504
$ 5,293
$ 5,309
Operating Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion Ratio
(GAAP)
Total cash provided by operating activities from continuing
operations (GAAP)$ 2,117
$ 2,019
$ 6,416
$ 6,688Net earnings from continuing operations (GAAP)1,183
1,086
3,600
3,899Operating cash flow from continuing operations to net
earnings from continuing operations conversion ratio1.79
1.86
1.78
1.72
Free Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion Ratio
(non-GAAP)
Free cash flow from continuing operations from above (non-
GAAP)$ 1,769
$ 1,504
$ 5,293
$ 5,309Net earnings from continuing operations (GAAP)1,183
1,086
3,600
3,899Free cash flow from continuing operations to net earnings
from continuing operations conversion ratio (non-GAAP) 1.50
1.38
1.47
1.36
Note: The Company defines free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations ("capital expenditures") plus the proceeds from sales of plant, property and equipment from continuing operations ("capital disposals"). All amounts presented above reflect only continuing operations. Statement Regarding Non-GAAP MeasuresEach of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; andwith respect to free cash flow from continuing operations and related non-GAAP cash flow measures (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of the FCF Measure is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company's executive compensation program.The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to "restructuring charges" and "other adjustments", we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS (unaudited)($ in millions, except per share amount)
As of December 31
2025
2024ASSETS
Current assets:
Cash and equivalents$ 4,615
$ 2,078Trade accounts receivable, less allowance for doubtful accounts of $114 as of
December 31, 2025 and $113 as of December 31, 20243,913
3,537Inventories2,489
2,330Prepaid expenses and other current assets1,739
1,552Total current assets12,756
9,497Property, plant and equipment, net5,531
4,990Other long-term assets4,209
3,990Goodwill43,151
40,497Other intangible assets, net17,817
18,568Total assets$ 83,464
$ 77,542
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Notes payable and current portion of long-term debt$ 2
$ 505Trade accounts payable1,844
1,753Accrued expenses and other liabilities4,961
4,540Total current liabilities6,807
6,798Other long-term liabilities5,700
5,694Long-term debt18,416
15,500Stockholders' equity:
Common stock - $0.01 par value, 2.0 billion shares authorized; 886.9 million issued
and 706.9 million outstanding as of December 31, 2025; 884.3 million issued and
719.1 million outstanding as of December 31, 20249
9Additional paid-in capital17,194
16,727Treasury stock(11,353)
(8,163)Retained earnings46,891
44,188Accumulated other comprehensive income (loss)(207)
(3,218)Total Danaher stockholders' equity52,534
49,543Noncontrolling interests7
7Total stockholders' equity52,541
49,550Total liabilities and stockholders' equity$ 83,464
$ 77,542
This information is presented for reference only. Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information. DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF EARNINGS (unaudited)($ and shares in millions, except per share amounts)
Three-Month Period Ended
Year Ended
December 31,
2025
December 31,
2024
December 31,
2025
December 31,
2024
Sales$ 6,838
$ 6,538
$ 24,568
$ 23,875
Cost of sales(2,872)
(2,648)
(10,045)
(9,669)
Gross profit3,966
3,890
14,523
14,206
Operating costs:
Selling, general and administrative expenses(2,026)
(2,023)
(8,235)
(7,759)
Research and development expenses(438)
(442)
(1,598)
(1,584)
Operating profit1,502
1,425
4,690
4,863
Nonoperating income (expense):
Other income (expense), net(87)
(63)
(222)
(56)
Interest expense(55)
(61)
(265)
(278)
Interest income13
14
30
117
Earnings from continuing operations before
income taxes1,373
1,315
4,233
4,646
Income taxes(190)
(229)
(633)
(747)
Net earnings from continuing operations1,183
1,086
3,600
3,899
Earnings from discontinued operations, net of
income taxes14
—
14
—
Net earnings1,197
1,086
3,614
3,899
Net earnings per common share from
continuing operations:
Basic$ 1.67
$ 1.50
$ 5.05
$ 5.33
Diluted$ 1.66
$ 1.49
$ 5.03(a)$ 5.29(a)Net earnings per common share from
discontinued operations:
Basic$ 0.02
$ —
$ 0.02
$ —
Diluted$ 0.02
$ —
$ 0.02
$ —
Net earnings per common share:
Basic$ 1.69
$ 1.50
$ 5.07
$ 5.33
Diluted$ 1.68
$ 1.49
$ 5.05(a)$ 5.29(a)Average common stock and common
equivalent shares outstanding:
Basic707.3
722.7
712.7
731.0
Diluted711.0
728.2
716.1
737.2
(a) Net earnings per common share amount for the relevant three-month periods do not add to the full year period amount due to rounding.
This information is presented for reference only. Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information. DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)($ in millions)
Year Ended December 31
2025
2024Cash flows from operating activities:
Net earnings$ 3,614
$ 3,899Less: earnings from discontinued operations, net of income taxes(14)
—Net earnings from continuing operations3,600
3,899Noncash items:
Depreciation750
721Amortization of intangible assets1,697
1,631Amortization of acquisition-related inventory fair value step-up—
25Stock-based compensation expense298
288Investment losses, pretax gain on sale of product line and other228
57Impairment charges562
265Change in deferred income taxes(440)
(483)Change in trade accounts receivable, net(216)
331Change in inventories(58)
147Change in trade accounts payable9
19Change in prepaid expenses and other assets(55)
274Change in accrued expenses and other liabilities41
(486)Total operating cash provided by continuing operations6,416
6,688Cash flows from investing activities:
Cash paid for acquisitions—
(558)Payments for additions to property, plant and equipment(1,156)
(1,392)Proceeds from sales of property, plant and equipment33
13Payments for purchases of investments(127)
(331)Proceeds from sales of investments12
253Proceeds from sale of product line9
—All other investing activities33
34Total cash used in investing activities from continuing operations(1,196)
(1,981)Cash flows from financing activities:
Proceeds from the issuance of common stock in connection with stock-based
compensation85
162Payment of dividends(878)
(768)Net (repayments of) proceeds from borrowings (maturities of 90 days or less)(11)
5Borrowings (maturities longer than 90 days)1,556
—Repayments of borrowings (maturities longer than 90 days)(500)
(1,674)Payments for repurchase of common stock(3,088)
(5,979)All other financing activities(125)
(131)Net cash used in financing activities for continuing operations(2,961)
(8,385)Effect of exchange rate changes on cash and equivalents278
(108)Net change in cash and equivalents2,537
(3,786)Beginning balance of cash and equivalents2,078
5,864Ending balance of cash and equivalents$ 4,615
$ 2,078
This information is presented for reference only. Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information. DANAHER CORPORATION AND SUBSIDIARIESSEGMENT INFORMATION (unaudited)($ in millions)
Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024
Sales (GAAP):
Biotechnology$ 2,033
$ 1,869
$ 7,293
$ 6,759
Life Sciences2,085
2,032
7,334
7,329
Diagnostics2,720
2,637
9,941
9,787
Total Company$ 6,838
$ 6,538
$ 24,568
$ 23,875
Operating Profit (GAAP):
Biotechnology$ 540
$ 508
$ 1,864
$ 1,685
Life Sciences336
376
520
879
Diagnostics713
624
2,650
2,625
Other(87)
(83)
(344)
(326)
Total Company$ 1,502
$ 1,425
$ 4,690
$ 4,863
Operating Profit Margins (GAAP):
Biotechnology26.6 %
27.2 %
25.6 %
24.9 %
Life Sciences16.1 %
18.5 %
7.1 %
12.0 %
Diagnostics26.2 %
23.7 %
26.7 %
26.8 %
Total Company22.0 %
21.8 %
19.1 %
20.4 %
Amortization of Intangible Assets (GAAP):
Biotechnology$ 230
$ 213
$ 902
$ 863
Life Sciences151
148
604
576
Diagnostics47
47
191
192
Total Company$ 428
$ 408
$ 1,697
$ 1,631
Other Operating Profit Adjustments4:
Biotechnology$ —
$ —
$ 101C$ —
Life Sciences14C—
446C247C, HDiagnostics(10)E99C, F5C, E99C, FTotal Company$ 4
$ 99
$ 552
$ 346
Adjusted Operating Profit (non-GAAP)5:
Biotechnology$ 770
$ 721
$ 2,867
$ 2,548
Life Sciences501
524
1,570
1,702
Diagnostics750
770
2,846
2,916
Other(87)
(83)
(344)
(326)
Total Company$ 1,934
$ 1,932
$ 6,939
$ 6,840
Depreciation (GAAP):
Biotechnology$ 39
$ 38
$ 149
$ 151
Life Sciences48
44
185
167
Diagnostics106
102
407
394
Other2
3
9
9
Total Company$ 195
$ 187
$ 750
$ 721
4 Refer to the Reconciliation of Adjusted Diluted Net Earnings per Common Share for footnotes containing descriptions of the components of Other
Operating Profit Adjustments. All Other Operating Profit Adjustments are included within Selling, general and administrative expenses within the
Consolidated Statements of Earnings, other than $14 million recorded in the three-month period ended December 31, 2025 in the Life Sciences
segment, $29 million recorded in the year ended December 31, 2025 in the Life Sciences and Biotechnology segments and $25 million recorded in the
year ended December 31, 2024 in the Life Sciences segment, which are recorded within Cost of sales.5 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating
Profit Adjustments (as defined).
This information is presented for reference only. Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information.
View original content:https://www.prnewswire.com/news-releases/danaher-reports-fourth-quarter-and-full-year-2025-results-302671883.htmlSOURCE Danaher Corporation
Original: Danaher Reports Fourth Quarter and Full Year 2025 Results
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
iHub News
4月前
DeafTrader2
2年前
bar1080
2年前
gfp927z
5年前
Ferda
5年前
Lime Time
5年前
メールアドレスで登録
